SeaStar Medical Holding Corporation Warrant

PepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.

SeaStar Medical announced progress in its NEUTRALIZE-AKI pivotal trial for acute kidney injury treatment, reaching over 60% enrollment with 125 of 200 anticipated patients and 16 clinical trial sites activated.